Free Trial
OTCMKTS:EKTAY

Elekta AB (publ) (EKTAY) Stock Price, News & Analysis

$6.29
-0.18 (-2.78%)
(As of 09/6/2024 ET)
Today's Range
$6.29
$6.35
50-Day Range
$5.86
$6.78
52-Week Range
$5.86
$8.62
Volume
1,341 shs
Average Volume
9,515 shs
Market Capitalization
$2.41 billion
P/E Ratio
19.66
Dividend Yield
1.75%
Price Target
N/A

Elekta AB (publ) MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.00% of Shares Sold Short
Dividend Strength
Moderate
Based on Four Factors
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
15.00%
From $0.40 to $0.46 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.51 out of 5 stars

EKTAY stock logo

About Elekta AB (publ) Stock (OTCMKTS:EKTAY)

Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity for real-time MR visualization; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for image guided radiation therapy; treatment and workflow management solutions; radiation and medical oncology; and other patient services. It also provides Elekta Studio, an image guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Venezia applicator that enables the oncologist to treat locally advanced cervical cancer; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; Geneva, an applicator for cervical cancer treatment; veterinary radiation therapy products; and Elekta Kaiku for personalized cancer care. In addition, the company offers stereotactic radiosurgery, such as Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for radiosurgeons; and Elekta Esprit. Further, it provides neurosurgery products comprising Leksell Vantage Stereotactic System for intracranial neurosurgery; and Leksell Stereotactic System for minimally invasive stereotactic neurosurgery. The company was incorporated in 1972 and is headquartered in Stockholm, Sweden.

EKTAY Stock Price History

EKTAY Stock News Headlines

Kepler Capital Sticks to Its Hold Rating for Elekta AB (0O5H)
"Doomsday indicator” flashing for the first time since the Great Depression...
It's been a bloodbath in the markets. The seven most valuable US tech companies lost a combined $1 trillion - in a single day. And things could get a lot worse...
Here's what to expect from Elekta A B's earnings
Elekta's Q1 beats estimates, shares jump
Elekta AB (publ) goes ex dividend Monday
"Doomsday indicator” flashing for the first time since the Great Depression...
It's been a bloodbath in the markets. The seven most valuable US tech companies lost a combined $1 trillion - in a single day. And things could get a lot worse...
Is Elekta (EKTAY) Stock Undervalued Right Now?
Is Elekta (EKTAY) a Great Value Stock Right Now?
Elekta AB ADR EKTAY
See More Headlines
Receive EKTAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Elekta AB (publ) and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/28/2024
Today
9/07/2024
Ex-Dividend for 9/27 Dividend
9/09/2024
Dividend Payable
9/27/2024
Fiscal Year End
4/30/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Medical laboratories
Sub-Industry
N/A
Current Symbol
OTCMKTS:EKTAY
Employees
4,540
Year Founded
N/A

Profitability

Net Income
$122.52 million
Pretax Margin
9.21%

Debt

Sales & Book Value

Annual Sales
$1.70 billion
Cash Flow
$0.57 per share
Book Value
$2.64 per share

Miscellaneous

Free Float
N/A
Market Cap
$2.41 billion
Optionable
Not Optionable
Beta
1.21
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Dr. Laurent Leksell (Age 72)
    Founder & Chairman
    Comp: $1.64M
  • Mr. Gustaf Salford (Age 47)
    President & CEO
    Comp: $14.62M
  • Mr. Tobias Hagglov (Age 46)
    Chief Financial Officer
  • Mr. Peter Nyquist (Age 59)
    Head of Investor Relations
  • Mr. Jonas Bolander (Age 58)
    Executive VP of Group Functions, Secretary & General Counsel
  • Mr. Mattias Thorsson
    VP and Head of Corporate Communications & Public Affairs
  • Ms. Anna Conneryd Lundgren (Age 39)
    Executive VP & Chief People Officer
  • Mr. John Lapré (Age 60)
    President of Brachy & Neuro Solutions
  • Mr. Maurits Wolleswinkel (Age 53)
    President of Linac & Software Solutions
  • Mr. Habib Nehme (Age 60)
    Chief Commercial Officer

EKTAY Stock Analysis - Frequently Asked Questions

How have EKTAY shares performed this year?

Elekta AB (publ)'s stock was trading at $8.1495 at the beginning of the year. Since then, EKTAY shares have decreased by 22.8% and is now trading at $6.29.
View the best growth stocks for 2024 here
.

How were Elekta AB (publ)'s earnings last quarter?

Elekta AB (publ) (OTCMKTS:EKTAY) issued its quarterly earnings data on Wednesday, August, 28th. The company reported $0.04 earnings per share (EPS) for the quarter. The firm earned $359.76 million during the quarter. Elekta AB (publ) had a trailing twelve-month return on equity of 12.30% and a net margin of 6.25%.

How do I buy shares of Elekta AB (publ)?

Shares of EKTAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:EKTAY) was last updated on 9/7/2024 by MarketBeat.com Staff

From Our Partners